EGFR and melanoma: EGFR inhibitors are classified into two major groups: the first with monoclonal antibodies, such as cetuximab and panitumumab, and the second with small molecule tyrosine kinase inhibitors [112] that showed different efficacy towards melanoma cells as reported in preclinical and clinical studies.